A detailed history of Vanguard Group Inc transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,033,068 shares of LBPH stock, worth $122 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,033,068
Previous 1,925,147 5.61%
Holding current value
$122 Million
Previous $52 Million 30.22%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$27.58 - $39.5 $2.98 Million - $4.26 Million
107,921 Added 5.61%
2,033,068 $67.8 Million
Q2 2024

Aug 13, 2024

BUY
$17.0 - $27.03 $3.41 Million - $5.43 Million
200,716 Added 11.64%
1,925,147 $52 Million
Q1 2024

May 10, 2024

BUY
$18.89 - $26.06 $17.7 Million - $24.4 Million
937,998 Added 119.27%
1,724,431 $37.2 Million
Q4 2023

Feb 14, 2024

BUY
$3.68 - $6.5 $19,724 - $34,840
5,360 Added 0.69%
786,433 $4.74 Million
Q3 2023

Nov 14, 2023

BUY
$5.49 - $7.49 $625,168 - $852,916
113,874 Added 17.07%
781,073 $4.34 Million
Q2 2023

Aug 14, 2023

BUY
$4.19 - $10.05 $1.13 Million - $2.7 Million
268,720 Added 67.44%
667,199 $4.9 Million
Q1 2023

May 15, 2023

BUY
$3.84 - $5.96 $352,880 - $547,700
91,896 Added 29.97%
398,479 $1.6 Million
Q4 2022

Feb 10, 2023

BUY
$2.95 - $5.5 $11,313 - $21,092
3,835 Added 1.27%
306,583 $999,000
Q3 2022

Nov 14, 2022

SELL
$2.95 - $4.7 $2,952 - $4,704
-1,001 Reduced 0.33%
302,748 $1.13 Million
Q4 2021

Feb 14, 2022

BUY
$4.75 - $9.45 $619,400 - $1.23 Million
130,400 Added 75.22%
303,749 $1.48 Million
Q3 2021

Nov 12, 2021

BUY
$8.65 - $11.36 $67,504 - $88,653
7,804 Added 4.71%
173,349 $1.53 Million
Q2 2021

Aug 13, 2021

BUY
$7.95 - $17.3 $1.32 Million - $2.86 Million
165,545 New
165,545 $1.51 Million

Others Institutions Holding LBPH

About Longboard Pharmaceuticals, Inc.


  • Ticker LBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,586,000
  • Market Cap $815M
  • Description
  • Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...
More about LBPH
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.